Drug Safety

, Volume 25, Issue 2, pp 91–110

Effects of Psychotropic Drugs on Seizure Threshold

  • Francesco Pisani
  • Giancarla Oteri
  • Cinzia Costa
  • Giorgio Di Raimondo
  • Raoul Di Perri
Review Article

Abstract

Psychotropic drugs, especially antidepressants and antipsychotics, may give rise to some concern in clinical practice because of their known ability to reduce seizure threshold and to provoke epileptic seizures. Although the phenomenon has been described with almost all the available compounds, neither its real magnitude nor the seizurogenic potential of individual drugs have been clearly established so far. In large investigations, seizure incidence rates have been reported to range from ∼0.1 to ∼1.5% in patients treated with therapeutic doses of most commonly used antidepressants and antipsychotics (incidence of the first unprovoked seizure in the general population is 0.07 to 0.09%). In patients who have taken an overdose, the seizure risk rises markedly, achieving values of ∼4 to ∼30%. This large variability, probably due to methodological differences among studies, makes data confusing and difficult to interpret. Agreement, however, converges on the following: seizures triggered by psychotropic drugs are a dose-dependent adverse effect; maprotiline and clomipramine among antidepressants and chlorpromazine and clozapine among antipsychotics that have a relatively high seizurogenic potential; phenelzine, tranylcypromine, fluoxetine, paroxetine, sertraline, venlafaxine and trazodone among antidepressants and fluphenazine, haloperidol, pimozide and risperidone among antipsychotics that exhibit a relatively low risk. Apart from drug-related factors, seizure precipitation during psychotropic drug medication is greatly influenced by the individual’s inherited seizure threshold and, particularly, by the presence of seizurogenic conditions (such as history of epilepsy, brain damage, etc.). Pending identification of compounds with less or no effect on seizure threshold and formulation of definite therapeutic guidelines especially for patients at risk for seizures, the problem may be minimised through careful evaluation of the possible presence of seizurogenic conditions and simplification of the therapeutic scheme (low starting doses/slow dose escalation, maintenance of the minimal effective dose, avoidance of complex drug combinations, etc.). Although there is sufficient evidence that psychotropic drugs may lower seizure threshold, published literature data have also suggested that an appropriate psychotropic therapy may not only improve the mental state in patients with epilepsy, but also exert antiepileptic effects through a specific action. Further scientific research is warranted to clarify all aspects characterising the complex link between seizure threshold and psychotropic drugs.

References

  1. 1.
    Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981Google Scholar
  2. 2.
    Edwards JG, Long KS, Sedgwick EM, et al. Antidepressants and convulsive seizures: clinical, electroencephalographic and pharmacological aspects. Clin Neuropharm 1986; 9: 329–60CrossRefGoogle Scholar
  3. 3.
    Robertson MM. The organic contribution to depressive illness in patients with epilepsy. J Epilepsy 1989; 2: 189–223CrossRefGoogle Scholar
  4. 4.
    Matthews WS, Barabas G. Suicide and epilepsy: a review of the literature. Psychosomatics 1981; 22: 515–24PubMedGoogle Scholar
  5. 5.
    Anton-Stephens D. Preliminary observations on the psychiatric use of chlorpromazine. J Ment Sci 1953; 100: 543–7Google Scholar
  6. 6.
    Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959; 105: 1123–6PubMedGoogle Scholar
  7. 7.
    Blair D. Treatment of severe depression by imipramine: an investigation of 100 cases. J Ment Sci 1960; 106: 891–905Google Scholar
  8. 8.
    Sharp WL. Convulsions associated with anti-depressant drugs. Am J Psychiatry 1960; 117: 458–9Google Scholar
  9. 9.
    Kiloh LG, Davison K, Ossleton JW. An electroencephalographic study on the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961; 12: 165–72Google Scholar
  10. 10.
    Davison K. EEG activation after intravenous amitriptyline. Electroencephalogr Clin Neurophysiol 1965; 19: 298–300PubMedCrossRefGoogle Scholar
  11. 11.
    Redding FK. EEG activation with amitriptyline. Electroencephalogr Clin Neurophysiol 1969; 26: 630–6CrossRefGoogle Scholar
  12. 12.
    Legg NJ, Swash M. Clinical note: seizures and EEG activation after trimipramine. Epilepsia 1974; 15: 131–5PubMedCrossRefGoogle Scholar
  13. 13.
    Rumpl E, Hinterhuber H. Unusual spike-wave stupor in a patient with manic-depressive psychosis treated with amitriptyline. J Neurol 1981; 226: 131–5PubMedCrossRefGoogle Scholar
  14. 14.
    Meldrum B, Anlezark G, Trimble M. Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsy in papio papio. Eur J Pharmacol 1975; 32: 203–13PubMedCrossRefGoogle Scholar
  15. 15.
    Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1–66PubMedCrossRefGoogle Scholar
  16. 16.
    Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiat 1983; 44: 197–201Google Scholar
  17. 17.
    Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressant and convulsions. J Clin Pharmacol 1983; 3: 182–5Google Scholar
  18. 18.
    Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99PubMedGoogle Scholar
  19. 19.
    Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86–90PubMedCrossRefGoogle Scholar
  20. 20.
    Physician’s Desk Reference. Prozac. Montvale (NJ): Medical Economics, 1992: 921Google Scholar
  21. 21.
    Edwards JG, Inman WHW, Wilton L, et al. Prescription-event monitoring of 10401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387–95PubMedCrossRefGoogle Scholar
  22. 22.
    Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77PubMedCrossRefGoogle Scholar
  23. 23.
    Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41(3): 369–71PubMedCrossRefGoogle Scholar
  24. 24.
    Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247–9PubMedCrossRefGoogle Scholar
  25. 25.
    Stimmel GL, Dopheide JA. Psychotropic drug-induced reductions in seizure threshold: incidence and consequences. CNS Drugs 1996; 5: 37–50CrossRefGoogle Scholar
  26. 26.
    Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999; 53Suppl. 2: 68–75Google Scholar
  27. 27.
    Quitkin F, Rifkin A, Klein DF. Very high dosage versus standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975; 32: 1276–81PubMedCrossRefGoogle Scholar
  28. 28.
    Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Emerg Med 1998; 16: 498–501PubMedCrossRefGoogle Scholar
  29. 29.
    Leber P. Adverse drug reactions -‘time-less’ risks (a hazard of risk assessment: the example of seizure and antidepressants). Psychopharmacol Bull 1985; 21: 334–8PubMedGoogle Scholar
  30. 30.
    Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991; 9(1): 37–52PubMedGoogle Scholar
  31. 31.
    Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93–4CrossRefGoogle Scholar
  32. 32.
    Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19: 696–700PubMedCrossRefGoogle Scholar
  33. 33.
    Delay J, Deniker P. Efficacy of Tofranil in the treatment of various types of depression: a comparison with other antidepressant drugs. Can Psychiatr Ass J 1959; 4: 100–12Google Scholar
  34. 34.
    Freyhan FA. Clinical effectiveness of Tofranil in the treatment of depressive psychoses. Can Psychiatr Ass J 1959; 4: 86–9Google Scholar
  35. 35.
    Burley DM. A brief note on the problem of epilepsy in antidepressant treatment. In: Jukes A, editor. Depression: the biochemical and physiologic role of Ludiomil. Horsham (UK): Ciba, 1977: 201–3Google Scholar
  36. 36.
    Jabbari B, Bryan G, Mars LE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1PubMedCrossRefGoogle Scholar
  37. 37.
    Lowry MR, Dunner FJ. Seizures during tricyclic therapy. Am J Psychat 1980; 137: 1461–2Google Scholar
  38. 38.
    Jus A, Villeneuve A, Gautier J, et al. Influence of lithium carbonate on patients with temporal epilepsy. Can Psychiatr Assoc J 1973; 18: 77–8PubMedGoogle Scholar
  39. 39.
    Betts TA, Kalra PL, Cooper R, et al. Epileptic fits as a probable side-effect of amitriptyline: report of seven cases. Lancet 1968; I: 390–2CrossRefGoogle Scholar
  40. 40.
    Dallos V, Heathfield K. Iatrogenic epilepsy due to antidepressant drugs. BMJ 1969; 4: 80–2PubMedCrossRefGoogle Scholar
  41. 41.
    Edwards JG, Glen-Bott M. Mianserin and convulsive seizures. Br J Clin Pharmacol 1983; 15: 299–311CrossRefGoogle Scholar
  42. 42.
    Alldredge BK. Drug induced seizures: controversies in their identification and management. Pharmacotherapy 1997; 17: 857–60PubMedGoogle Scholar
  43. 43.
    Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8PubMedCrossRefGoogle Scholar
  44. 44.
    Michals ML, Crismon ML, Roberts S, et al. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993; 13: 198–203PubMedCrossRefGoogle Scholar
  45. 45.
    Franson KL, Hay DP, Neppe V, et al. Drug-induced seizures in the elderly: causative agents and optimal management. Drugs Aging 1995; 7(1): 38–48PubMedCrossRefGoogle Scholar
  46. 46.
    Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379–84PubMedCrossRefGoogle Scholar
  47. 47.
    Itil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. JAMA 1980; 244: 1460–3PubMedCrossRefGoogle Scholar
  48. 48.
    Physicians’ desk reference. Montvale (NJ): Medical Economics, 1999Google Scholar
  49. 49.
    Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52: 1323–9PubMedCrossRefGoogle Scholar
  50. 50.
    Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatr Bull 1995; 19: 355–7CrossRefGoogle Scholar
  51. 51.
    Trimble MR. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1978; 19: 241–50PubMedCrossRefGoogle Scholar
  52. 52.
    Starkey IR, Lawson AA. Poisoning with tricyclic and related antidepressant: a ten year review. Q J Med 1980; 193: 33–49Google Scholar
  53. 53.
    Biggs JT, Spiker DG, Petit JM, et al. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977; 238: 135–8PubMedCrossRefGoogle Scholar
  54. 54.
    Kurtzke JF. Seizures with promazine, preliminary report. J Nerv Ment Dis 1957; 125: 119–25PubMedCrossRefGoogle Scholar
  55. 55.
    Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160–2PubMedGoogle Scholar
  56. 56.
    Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment. Clin Neuropharmacol 1987; 10: 265–7CrossRefGoogle Scholar
  57. 57.
    Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tryciclic antidepressant and lithium treatment. J Clin Psychopharm 1988; 8: 446–7CrossRefGoogle Scholar
  58. 58.
    Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol 1996; 3: 272–4PubMedCrossRefGoogle Scholar
  59. 59.
    DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997; 19: 71–3PubMedCrossRefGoogle Scholar
  60. 60.
    Miyata H, Kubota F, Shibata N, et al. Non-convulsive status epilepticus induced by antidepressants. Seizure 1997; 6(5): 405–7PubMedCrossRefGoogle Scholar
  61. 61.
    Zivin L, Ajmone Marsan C. Incidence and prognostic significance of ‘epileptiform’ activity in the EEG of non-epileptic subjects. Brain 1968; 91: 751–77PubMedCrossRefGoogle Scholar
  62. 62.
    Reilly EL, Reed K, Kelley JT. EEG and psychotropic drugs. In: Hughes JR, Wilson WP, editors. EEG and evoked potentials in psychiatry and behavioral neurology. Boston: Butterworths, 1983: 79–99Google Scholar
  63. 63.
    Sedgwick EM, Edwards JG. Mianserin, maprotiline and the electroencephalogram. Br J Clin Pharmacol 1983; 15: 255–62CrossRefGoogle Scholar
  64. 64.
    Itil TM. Psychotropic drugs and the human EEG. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 499–513Google Scholar
  65. 65.
    Aguglia U, Gambardella A, Le Piane E, et al. Chlorpromazine versus sleep deprivation in activation of EEG in adult-onset partial epilepsy. J Neurol 1994; 241: 605–10PubMedCrossRefGoogle Scholar
  66. 66.
    Toone BK, Fenton GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977; 7: 265–70PubMedCrossRefGoogle Scholar
  67. 67.
    Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 1984; 25: 25–32PubMedCrossRefGoogle Scholar
  68. 68.
    Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures: an in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982; 39(2): 206–9PubMedCrossRefGoogle Scholar
  69. 69.
    Bauer G. EEG, drug effects, and central nervous system poisoning. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 479–89Google Scholar
  70. 70.
    Fink M. EEG profiles and bioavailability measures of psychoactive drugs. Mod Probl Pharmacopsychiatry 1974; 8: 76–98Google Scholar
  71. 71.
    Herrmann WM, Schaerer E. Pharmaco-EEG: computer EEG analysis to describe the projection of drug effects on a functional cerebral level in humans. In: Lopes da Silva FH, Storm van Leeuwen W, Remond A, editors. Handbook of electroencephalography and clinical neurophysiology, revised series. Vol. 2. Amsterdam: Elsevier, 1986: 385–445Google Scholar
  72. 72.
    Glaze DG. Drug effects. In: Daly DD, Pedley TA, editors. Current practice of clinical electroencephalography. 2nd ed. New York: Raven Press, 1990: 489–512Google Scholar
  73. 73.
    Helmchen H, Kanowski S. EEG changes under lithium (Li) treatment. Electroencephalogr Clin Neurophysiol 1971; 30: 269PubMedGoogle Scholar
  74. 74.
    Small JG. EEG and lithium CNS toxicity. Am J EEG Technol 1986; 26: 225–39Google Scholar
  75. 75.
    Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6: 250–6PubMedGoogle Scholar
  76. 76.
    Neufeld MY, Rabey JM, Orlov E, et al. Electroencephalographic findings with low-dose clozapine treatment in psychotic parkinsonian patients. Clin Neuropharmacol 1996; 19(1): 81–6PubMedCrossRefGoogle Scholar
  77. 77.
    Freudenreich O, Richard D, McEvoy W, et al. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42: 132–7PubMedCrossRefGoogle Scholar
  78. 78.
    Schuld A, Kuhn M, Haack M, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry 2000; 33: 109–11PubMedCrossRefGoogle Scholar
  79. 79.
    Pillmann F, Schlote K, Broich K, et al. Electroencephalogram alterations during treatment with olanzapine. Psychopharmacology 2000; 150: 216–9PubMedCrossRefGoogle Scholar
  80. 80.
    Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8: 296–8PubMedGoogle Scholar
  81. 81.
    Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995; 26: 234–7PubMedCrossRefGoogle Scholar
  82. 82.
    Trabert W, Hohagen F, Winkelmann G, et al. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995; 28: 95–7PubMedCrossRefGoogle Scholar
  83. 83.
    Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35: 237–40PubMedCrossRefGoogle Scholar
  84. 84.
    Atril PB, Julius DA. Maprotile hydrochloride associated with a clinical state of catatonic stupor and epileptic encephalogram. J Clin Psychopharmacol 1984; 4: 207–9Google Scholar
  85. 85.
    Trimble MR. New antidepressant drugs and the seizure threshold. Neuropharmacology 1980; 19: 1227–8PubMedCrossRefGoogle Scholar
  86. 86.
    Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy [letter]. Arch Gen Psych 1985; 42: 523CrossRefGoogle Scholar
  87. 87.
    De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43: 40–7PubMedCrossRefGoogle Scholar
  88. 88.
    Schindler BA, Ramcandani D. Partial complex status epilepticus in a lithium-toxic patient. Psychosomatics 1993; 4: 521–4CrossRefGoogle Scholar
  89. 89.
    Showron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18–22Google Scholar
  90. 90.
    Remick RA, Fine SH. Antipsychotic drugs and seizures. J Clin Psychiatry 1979; 40(2): 78–80PubMedGoogle Scholar
  91. 91.
    Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987; 9(2): 135–41PubMedCrossRefGoogle Scholar
  92. 92.
    Trimble MR. The psychoses of epilepsy and their treatment. Clin Neuropharmacol 1985; 8: 211–20PubMedCrossRefGoogle Scholar
  93. 93.
    Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy: a double-blind trial. J Affect Disord 1985; 9: 127–36PubMedCrossRefGoogle Scholar
  94. 94.
    Itil TM, Myers JP. Epileptic and anti-epileptic properties of psychotropic drugs. In: Mercier J, editor. Anticonvulsant drugs. International encyclopedia of pharmacology and therapeutics. Vol. 19, No. 2. Oxford: Pergamon, 1973: 599–622Google Scholar
  95. 95.
    Itil TM. Convulsive and anticonvulsive properties of neuropsychopharmaca. In: Niederland E, editor. Epilepsy: modern problems of pharmacopsychiatry. Vol. 4. New York: Karger, 1970: 270–305Google Scholar
  96. 96.
    Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95CrossRefGoogle Scholar
  97. 97.
    Frommer DA, Kulig KW, Marx GA, et al. Tricyclic antidepressant overdose: a review. JAMA 1987; 257: 521–6PubMedCrossRefGoogle Scholar
  98. 98.
    Goel KM, Shanks RM. Amitriptyline and imipramine poisoning in children. BMJ 1974; 1: 261–3PubMedCrossRefGoogle Scholar
  99. 99.
    Olson KR, Kearney TE, Dver JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12: 392–5PubMedCrossRefGoogle Scholar
  100. 100.
    Preskorn SH, Othmer SC, Lai CW, et al. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. J Clin Psychopharmacol 1984; 4: 262–4PubMedCrossRefGoogle Scholar
  101. 101.
    Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313: 474–9PubMedCrossRefGoogle Scholar
  102. 102.
    Darby JK, Pasta DJ, Dabiri L, et al. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995; 15(5): 334–40PubMedCrossRefGoogle Scholar
  103. 103.
    Richens A, Nawishy S, Trimble MR. Antidepressant drugs, convulsions, and epilepsy. Br J Clin Pharmacol 1983; 15: 295–8CrossRefGoogle Scholar
  104. 104.
    Perucca E, Manzo L, Crema A. Pharmacokinetic interaction between antiepileptic and psychotropic drugs. In: Trimble MR, editor. The psychopharmacology of epilepsy: Chichester: John Wiley & Sons, 1985: 95–105Google Scholar
  105. 105.
    Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479–87CrossRefGoogle Scholar
  106. 106.
    Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999; 40(10 Suppl): 71S–6SCrossRefGoogle Scholar
  107. 107.
    Baldessarini RJ, Teicher MH, Cassidy JW. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988; 8: 381–2PubMedCrossRefGoogle Scholar
  108. 108.
    Troupin AS, Ojemann LM. Paradoxical intoxication: a complication of anticonvulsant administration. Epilepsia 1975; 16: 753–8PubMedCrossRefGoogle Scholar
  109. 109.
    Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3Google Scholar
  110. 110.
    Dersun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993; 342: 442–3CrossRefGoogle Scholar
  111. 111.
    Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992; 55: 412–3PubMedCrossRefGoogle Scholar
  112. 112.
    Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: 1–10PubMedCrossRefGoogle Scholar
  113. 113.
    Fenton GJ. Psychiatric disorders of epilepsy: classification and phenomelogy. In: Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981: 12–26Google Scholar
  114. 114.
    Perrine K, Congett S. Neurobehavioral problems in epilepsy. Neurol Clin 1994; 12: 129–52PubMedGoogle Scholar
  115. 115.
    Pauig PM, Deluca MA, Osterheld RG. Thioridazine hydrochloride in the treatment of behavior disorders in epileptics. Am J Psychiatry 1961; 117: 832–3PubMedGoogle Scholar
  116. 116.
    Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepine on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8PubMedCrossRefGoogle Scholar
  117. 117.
    Millichap JG. Anticonvulsant drugs. In: Root WS, Hofmann FG, editors. Physiological pharmacology: a comprehensive treatise. New York: Academic Press, 1965: 97–173Google Scholar
  118. 118.
    Fromm GH, Amores CY, Thies W. Imipramine in epilepsy. Arch Neurol 1972; 27: 198–204PubMedCrossRefGoogle Scholar
  119. 119.
    Fromm GH, Rosen JA, Amores CY. A clinical and experimental investigation of the effect of imipramine on epilepsy. Epilepsia 1971; 12: 282–3Google Scholar
  120. 120.
    Fromm GH, Wessel HB, Glass JD, et al. Imipramine in absence and myoclonic-astatic seizures. Neurology 1978; 28: 953–7PubMedCrossRefGoogle Scholar
  121. 121.
    Setiey A, Courjon J. Clomipramine et petit mal. Lyon Med 1978; 239: 751–4Google Scholar
  122. 122.
    Sakakihara Y, Oka A, Kubota M, et al. Reduction of seizure frequency with clomipramine in patients with complex partial seizures. Brain Dev 1995; 17: 291–3PubMedCrossRefGoogle Scholar
  123. 123.
    Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995; 45: 1926–7PubMedCrossRefGoogle Scholar
  124. 124.
    Lange SC, Julien RM, Fowler GW. Biphasic effects of imipramine in experimental models of epilepsy. Epilepsia 1976; 17: 183–96PubMedCrossRefGoogle Scholar
  125. 125.
    Vernier VG. The pharmacology of antidepressant agents. Dis Nerv Syst 1961; 22: 7–13PubMedGoogle Scholar
  126. 126.
    Chen G, Ensor CR, Bohner B. Studies of drug effects on electrically induced extensor seizures and clinical implications. Arch Int Pharmacodyn Ther 1968; 172: 183–218PubMedGoogle Scholar
  127. 127.
    Stille G, Sayers A. The effect of antidepressant drugs on the convulsive excitability of brain structures. Int J Neuropharmacol 1964; 3: 605–9PubMedCrossRefGoogle Scholar
  128. 128.
    Meldrum BS, Anlezark GM, Adam HK, et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology 1982; 76: 212–7PubMedCrossRefGoogle Scholar
  129. 129.
    Woods TW, Jobe PC, Laird HE, et al. Anticonvulsant and proconvulsant doses of desipramine in the genetically epilepsyprone rat. Fed Proc 1983; 42: 363Google Scholar
  130. 130.
    Woods TW, Dailey JW, Reigel CE, et al. Anticonvulsant and proconvulsant effects of doxepin in genetically epilepsy prone rat (GEPR). Fed Proc 1985; 44: 1107Google Scholar
  131. 131.
    Emori K, Minabe Y, Tanii Y, et al. Effects of chronic treatment with haloperidol and methamphetamine on hippocampal kindled seizures in the cat. Epilepsy Res 1991; 8(3): 213–9PubMedCrossRefGoogle Scholar
  132. 132.
    George B, Kulkarni SK. Protective effect of clozapine against pentylenetetrazol convulsions and kindling. Meth Find Exp Clin Pharmacol 1998; 20(5): 395–401CrossRefGoogle Scholar
  133. 133.
    Koella WP, Glatt A, Klebs K, et al. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine and amitriptyline. Biol Psychiatry 1979; 14: 485–97PubMedGoogle Scholar
  134. 134.
    Jobe PC, Woods TW, Dailey JW. Pro-convulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. In: Porter RJ, Mattson J, Richard H, et al., editors. Advances in epileptology: 15th Epilepsy International Symposium. New York: Raven Press, 1984: 187–91Google Scholar
  135. 135.
    Marescaux C, Hirsch E, Fink S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990; 31: 768–77PubMedCrossRefGoogle Scholar
  136. 136.
    Lerman P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986; 27: 706–10PubMedCrossRefGoogle Scholar
  137. 137.
    Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1487–9PubMedCrossRefGoogle Scholar
  138. 138.
    Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3Google Scholar
  139. 139.
    Snead OC, Hosey LN. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916–21PubMedCrossRefGoogle Scholar
  140. 140.
    Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology 1992; 42: 2198–201PubMedCrossRefGoogle Scholar
  141. 141.
    Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate [letter]. Lancet 1982; I: 1306CrossRefGoogle Scholar
  142. 142.
    Koenig SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new cases. Epilepsia 1994; 35: 1005–15CrossRefGoogle Scholar
  143. 143.
    Chadwick DW, Cumming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979; 6: 552–3PubMedCrossRefGoogle Scholar
  144. 144.
    Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972; 13: 421–35PubMedCrossRefGoogle Scholar
  145. 145.
    Prior PF, Maclaine GN, Scott DF, et al. Tonic status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia 1972; 13: 467–72PubMedCrossRefGoogle Scholar
  146. 146.
    Bittencourt PRM, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1991; 22: 129–34CrossRefGoogle Scholar
  147. 147.
    Di Mario Jr FJ, Calancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988; 4: 249–51CrossRefGoogle Scholar
  148. 148.
    Alvarez N, Hartford E, Doubt C. Epileptic seizures induced by clonazepam. Clin Electroencephal 1981; 12: 57–65Google Scholar
  149. 149.
    Neufeld MY. Exacerbation of focal seizures due to carbamazepine treatment in an adult patient. Clin Neuropharmacol 1993; 16: 359–61PubMedCrossRefGoogle Scholar
  150. 150.
    Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5–17PubMedCrossRefGoogle Scholar
  151. 151.
    Trimble MR, Anlezark G, Meldrum BS. Seizure activity in photosensitive baboons following antidepressant drugs and the role of serotonergic mechanisms. Psychopharmacology 1977; 51: 159–64PubMedCrossRefGoogle Scholar
  152. 152.
    Altshuler HL, Killam EK, Killam KF. Biogenic amines and the photo-myoclonic syndrome in the baboon, papio papio. J Pharmacol Exp Ther 1976; 196: 156–66PubMedGoogle Scholar
  153. 153.
    Chadwick D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977; 1: 218–24PubMedCrossRefGoogle Scholar
  154. 154.
    Snead OC. On the sacred disease: the neurochemistry of epilepsy. Int Rev Neurobiol 1983; 24: 93–180PubMedCrossRefGoogle Scholar
  155. 155.
    Deahl M, Trimble MR. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991; 159: 433–5PubMedCrossRefGoogle Scholar
  156. 156.
    Wada Y, Nakamura M, Hasegowa H, et al. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992; 141: 21–4PubMedCrossRefGoogle Scholar
  157. 157.
    Dailey JW, Reith ME, Steidley KR, et al. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998; 39: 1054–63PubMedCrossRefGoogle Scholar
  158. 158.
    Dailey JW, Yan QS, Adams-Curtis LE, et al. Neurochemical correlates of antiepileptic drugs in the genetically epilepsyprone rat (GEPR). Life Sci 1996; 58: 259–66PubMedCrossRefGoogle Scholar
  159. 159.
    Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34(4): 275–81PubMedCrossRefGoogle Scholar
  160. 160.
    Sackeim HA, Decina P, Prohovnik I, et al. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983; 18: 1301–10PubMedGoogle Scholar
  161. 161.
    Post RM, Putnam F, Uhde TW, et al. Electroconvulsive therapy as an anticonvulsant: implications for its mechanism of action in affective illness. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. Ann NY Acad Sci 1986; 462: 376–88Google Scholar
  162. 162.
    Coffey CE, Lucke J, Weiner RD, et al. Seizure threshold in electroconvulsive therapy (ECT) II: the anticonvulsant effect of ECT. Biol Psychiatry 1995; 37: 777–88PubMedCrossRefGoogle Scholar
  163. 163.
    Harmant J, van Rijckevorsel-Harmant K, DeBarsy T, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect [letter]. Lancet 1990; 336: 386PubMedCrossRefGoogle Scholar
  164. 164.
    Reynolds EH. The pharmacological management of epilepsy associated with psychological disorders. Br J Psychiat 1982; 141: 549–57CrossRefGoogle Scholar
  165. 165.
    Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994; 39(4): 236–8PubMedGoogle Scholar
  166. 166.
    Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Francesco Pisani
    • 1
  • Giancarla Oteri
    • 1
  • Cinzia Costa
    • 1
  • Giorgio Di Raimondo
    • 1
  • Raoul Di Perri
    • 1
  1. 1.Department of Neurosciences and of Psychiatric and Anaesthesiological Sciences, First Neurological Clinic, Policiclinico UniversitarioThe University of MessinaContesse MessinaItaly

Personalised recommendations